Tobacco Documents Online

' 1 ~ ~ . ~ ~ ~ 3 l ) , DIRECTORY OF ON-GOING RESEARCH IN CANCER EPIDEMIOLOGY 1987 IARC DKFZ D. M. Parkin J. Wahrendorf In collaboration with E. Demaret A. Nagy-Tiborcz K. Schlaefer M. Villhauer-Lehr S. Whelan ttBRARY REFERENCE ONLY

UNITED STATES OF AMERICA Pennsylvania TERM: Aetiology; Clinical Effects; Delayed Effects; Environment; Familial, Genetic; Folbw-Up; Germinal'Mutation; Ti Mutation Epidemiology; Sib; Treatment I SITE: Wilms' Tumou !r TIME: 1979 - ` L f 1229 / 1987 / ID: 00022 T Hanle, W. Children s Hosp. of Philadelphia, The Joseph Stokes Jr. Research lnst:, Div. of Virology, 34th and Civic Center Bivd, 1 . Philadelphia, PA 19104, USA (TeL:(215) 596-9435/387•6180) k COLL: Henle, G.; Fleisher, G.; Klein, G.;',Pearson; G.R:; Horwitz, C.A,; Hirsch, M•S.; Berkel, A.I.; Lanier, A.K:; L Merino, F.; Albeck, H.; Levine, A. ! C II C Saro-Epid.miology of the Epstein-Barr Virus i The aims of these studies are (1) to apply EBV-specific serological tests measunng antibodies of different ~ C immune globulin classes against several virus-coded antigens to the diagnosis, prognosis and post-therapeutic j monitoring of patients with EBV-associated cancers; i.e. Burkitt's tymphoma, nasopharyngeal carcinoma and I now also B cell lymphomas that arise with enhanced freqpency in immunologically compromised patients. Whenever possible, malignant cells in touch preparations made from biopsies will be examined for the presence of the EBV-associated nuclear antigen (EBNA); (2) to determine the effects of immunological deficiencies, be they of genetic (e.g., ataxia telangiectasia, or Cheliak-Higashi~Syndrome), therapeutic (organ transplant reci- pients), or disease-related origins (such as Hodgkin's disease or Aquired Immunodeficiency Syndrome) upon , the immune responses to primary or reactivation of persistent EBV infections in efforts to obtain information on the mechanism(s) leading to the setf-limitation of infectious mononucleosis and the control of the regularly ensuing latent viral carrier state and to evaluate the EBV-specific serology as another parameter in the ~ assessment of immunological incompetence. TERM: Aetiology; Antibodies: Antigens; Immunosuppression; Infection; Virus j SITE: Burkitt'S Lymphoma; Hodgkin's Disease; Lymphomas; Nasopharynx Neoplasms LOCA: Denmark; Greenland; Sweden; Turkey; United States of America; Venezuela ~ TIME: 1966 - } ~ : 1230/'1987/ID:02480 ~ ~ London, W.T. Inst. for Cancer Research, Fox Chase Cancer Center; Univ: of Pennsylvania, School of Medicine, Clinical Research • Div., 77018urholme Ave, Philadelphia, PA 19111, USA (Tel.:(215) 728-2204) ~ COLL: Ablin, A.A. l' c Rrlation of HBV Merkers In Children with Hspatoblastoma or Primary Hepetocpltular Carcinoma ~ Primary, cancers of the liver are rare in children. In ~ collaboratron with the Children's Cancer Study Group an investigation of HBV markers, including HBV DNA, in serum and liver tissue in children with these tumours is E being carried out. About 39 patients per year will be studied They will be drawn from hospitals in the US participating in a protocol for the treatment of hepatoblastoma and hepatocellular carcinoma in children. TERM: Case Characteristics; Child; Infection; Virus SITE: Liver NeopVasms TIME: 1980 - 1987 ) > •1231 / 1987 / 1D: 00318 Meadows, A.T- Univ. of Pennsylvania, Children's Hosp., Div. ot Oncology, Childrens Cancer Research Center, 34th and Civic Center Blvd, Philadelphia, PA 19104, USA (Tel.:(215) 596-9644) COLL: Banfi, A.; Baum, E.; d'Angio, G.J.; Green, D.; LeMerle, J.; Marsden, H.B.; Morris-Jones, P.H.; Nesbit„M.; Newton, W.A.;, Obringer, A.; Sallan, S.; Sandberg, A.; Siegef, S:; Vawter„ G.; Voute„ P•A.; Woods; W:; Zipursky, A. Late Eff.cts of Successful Cancer Therapy In Children The success of multi-modal and adjuvant therapy in improving the prognosis of childhood cancer has been dramatic„with the current overall long-term survival proportion reaching 60%. Concomitant with improvements in survival rates, however~ has come the realization that children cured of primary malignancies may be at increased risk of second malignant neoplasms (SMN) which may be related to the radio/'chemotherapies they received6 to genetic predispositions or a combination of botti, A 12-member international consortium of institu- tions, the Late Effects Study Group, has been~ formed to study patterns of, occurrence and risk factors for development of, SMN among children, treated for a primary malignancy and surviving at least two years post diagnosis. A registry of suchipatients, now including 300 children, serves as the basis for investigating (1) the incidence of SMN; (2) histopathology of, SMN; (~) identification of risk factors for SMN, including therapy and genetic factors; (4) unusual tumour associations in children with SMN; (5) congenital anomalies associated with SMN;,(6) family history in,children with SMN, particularly with regard to cancer, genetic disorders, and congenitat anomalies. A paper appeared in Radiation, JiD. Boice Jr and J.F. Fraumeni, Jr; (Eds), Carcinogenesis: Epide- miology and'Biol; Significance, pp. 21 t•224, Raven Press, New York 1984. 394